Northpond Ventures
Andrew Lee is a Senior Associate at Northpond Ventures. Andrew is a Board Director at Culture Biosciences. Previously, he was an Associate at Booz Allen Hamilton working in the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA), where he supported the development and management of a high-risk, high-reward research funding portfolio in gene editing and synthetic biology. Earlier, Andrew worked at Sangamo Biosciences (now Sangamo Therapeutics). Andrew earned a Ph.D. in microbiology and immunology from Columbia University. He received a B.A. with honors in molecular and cell biology, with an emphasis in biochemistry and molecular biology, at University of California, Berkeley.
This person is not in the org chart
This person is not in any offices
Northpond Ventures
Northpond Ventures is a leading global science, medical, and technology-driven venture firm dedicated to building and empowering breakthrough companies in life sciences and technology. Northpond has in excess of $1 billion of committed capital, with over 21 businesses represented in its portfolio. The firm’s investments target the greatest scientists, innovators, and entrepreneurs in life sciences, diagnostics, AI and machine learning, therapeutics, and affiliated sectors. Northpond has become among the most active investors in the life sciences and molecular diagnostics industries.